Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
Graviton has raised $39.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2024.
Graviton's investors include Sanofi.
Graviton is headquartered in New York, United States.
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
Graviton is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Graviton — Funding & Investors." VCBacked, February 1, 2024, https://www.vcbacked.co/company/graviton-new-york. Accessed November 14, 2026.
VCBacked. (2024). Graviton — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/graviton-new-york
{{cite web |title=Graviton — Funding & Investors |url=https://www.vcbacked.co/company/graviton-new-york |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Graviton? Request a listing update